News
Announcement of recruitment of participants for BNCT clinical trial targeting angiosarcoma
CICS Co., Ltd., a member of the Resort Trust Group,Clinical trial of Boron Neutron Capture Therapy (BNCT) for patients diagnosed with angiosarcoma This is carried out at the National Cancer Center Hospital.
We are currently recruiting people to participate in this clinical trial.
For further details and contact methods, please see below.
*Please refrain from reusing without permission.
Hemangiosarcoma Clinical Trial Recruitment (PDF: 2.4MB)
Application period: Until July 2024 (planned)
- What is Boron Neutron Capture Therapy (BNCT)?
BNCT is attracting attention as a cancer treatment method that is completed in one neutron irradiation in principle and places little strain on the body. CICS Co., Ltd. is working on this clinical trial to bring hope to patients who do not have effective treatment options.
- Related news releases about BNCT
●CICS Co., Ltd. (a consolidated subsidiary of Resorttrust Co., Ltd.) has begun a domestic Phase II clinical trial of boron neutron capture therapy (BNCT) for angiosarcoma.
https://www.resorttrust.co.jp/ps/qn3x/guest/news/dldata.cgi?CCODE=2&NCODE=325
●The cancer treatment device (BNCT system) being developed by the Resort Trust Group has been designated a "rare disease medical device."
https://www.resorttrust.co.jp/ps/qn3x/guest/news/dldata.cgi?CCODE=2&NCODE=368
*The content of this page is current as of July 2023, 12.